Imugene Ltd represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company aims to revolutionize cancer treatment through its cutting-edge immunotherapy technologies. Imugene prioritizes scientific expertise and fosters strategic partnerships to advance its pipeline of novel and targeted therapies. The company's commitment to improving treatment outcomes for patients is evidenced by its emphasis on clinical development, rigorous research, and commercialization of innovative products. Imugene's inclusive approach promotes open communication and collaboration among researchers, clinicians, and industry experts, reinforcing its dedication to making a significant impact in the fight against cancer.

Imugene Ltd is primarily present in Australia, United States, and Europe.

Imugene Ltd has achieved several significant milestones. The company successfully completed a Phase 1b study for its HER-Vaxx cancer immunotherapy in gastric cancer patients. Imugene also received approval from the US FDA to initiate its Phase 2 study for HER-Vaxx in gastric cancer. Additionally, Imugene has entered collaborations with renowned academic institutions, including City of Hope, to conduct preclinical and clinical trials for various cancer treatments. The company has made considerable progress in advancing its innovative immunotherapy pipeline, which shows great potential in the field of oncology. Imugene Ltd continues to strive for excellence and breakthroughs in cancer treatments.

Imugene Ltd is a biopharmaceutical company dedicated to developing innovative immunotherapies to treat cancer. Founded in 1983, Imugene has a rich history in the field of oncology research and drug development. The company focuses on creating targeted immunotherapies that harness the power of the immune system to fight cancer cells. Imugene is committed to addressing unmet medical needs and improving patient outcomes. With a strong team of experienced scientists and a robust pipeline of promising drug candidates, Imugene aims to revolutionize cancer treatment and provide hope to patients worldwide. Imugene Ltd continues to strive towards its mission of developing much-needed advancements in the oncology field.

The main competitors of Imugene Ltd in the market include major biopharmaceutical companies such as Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb Company, and Pfizer Inc. These companies also specialize in developing innovative treatments and therapies for various diseases and disorders.

Imugene Ltd is primarily active in the biotechnology industry.

Imugene Ltd is a biotechnology company specializing in the development and commercialization of innovative immunotherapies for the treatment of various cancers. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to create targeted and personalized immunotherapies that activate the body's own immune system to fight cancer. Imugene aims to improve patient outcomes and address the unmet medical needs in oncology by advancing their immunotherapy pipeline. With a focus on developing novel treatments and strategic partnerships, Imugene is dedicated to making a significant impact in the field of cancer immunotherapies.

Imugene KGV ir -2,04.

Imugene KUV ir 0.

AlleAktien kvalitātes vērtējums Imugene ir 4/10.

Pašreiz nevar aprēķināt apgrozījumu Imugene.

Imugene peļņa ir -149,68 milj. AUD.

Imugene Ltd is an Australian biopharmaceutical company that focuses on researching, developing, and marketing innovative therapeutic solutions for the treatment of cancer and infectious diseases. The company uses a unique technology platform to responsibly develop immuno-oncology products. Imugene is headquartered in Sydney, Australia, and has additional offices in the USA and Europe. The four main business areas of Imugene are: 1) Immuno-Oncology Products, 2) Immunomodulating Solutions in Cancer, 3) Infectious Diseases, and 4) Partner Programs. Imugene aims to expand its portfolio of immunotherapeutics through new product development and collaborations. It strives to revolutionize the treatment of cancer and infectious diseases with its unique technology platform and comprehensive portfolio of immunotherapeutics. Imugene is well-positioned to become a leading player in the biopharmaceutical industry with its presence in Australia, the USA, and Europe.

Imugene izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Imugene vai uzņēmums nedod dividendes.

Imugene ISIN ir AU000000IMU9.

Imugene WKN ir 891460.

Imugene simbols ir IMU.AX.

Pēdējo 12 mēnešu laikā Imugene maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Imugene plāno maksāt dividendes 0 AUD apmērā.

Imugene pašreizējā dividendu rentabilitāte ir .

Imugene maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Imugene pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

Imugene tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Imugene apmērā 0 AUD, kas tika izmaksāta 15.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 15.11.2024..

Pēdējās dividendes izmaksa notika 15.11.2024..

Gadā 2023, Imugene izmaksāja 0 AUD dividendes.

Imugene dividendes tiek izmaksātas AUD.